Appraisal 127

 

NICE (Single) Technology Appraisal Guidance 127: Natalizumab for the treatment of adults with highly active relapsing-remitting multiple sclerosis

This NICE guidance was published on 22 August 2007. The web reference for the appraisal and other related documents is: http://www.nice.org.uk/TA127

NHSScotlandshould note that:

1. Recommendations of NICE Single Technology Appraisals (STAs) have no status in NHSScotland.

2. NHS boards should adhere to the Scottish Medicines Consortium (SMC) advice.

SMC published a Statement of Advice (329/06) on this medication for this indication in September 2007. This stated that:

Natalizumab (Tysabri®) is accepted for restricted use within NHSScotland as single disease modifying therapy in highly active relapsing remitting multiple sclerosis (RRMS) only in patients with rapidly evolving severe RRMS defined by two or more disabling relapses in one year and with one or more gadolinium-enhancing lesions on brain magnetic resonance imaging (MRI) or a significant increase in T2 lesion load compared with a previous MRI.

Access the advice of SMC:

3. There is no material difference between the recommendations of the NICE STA and SMC. 

Published Date: 22 August 2007

Evidence

Reviewed for Scotland

This advice has been reviewed under our procedure for processing NICE appraisals to ensure it is relevant for the Scottish healthcare landscape.

Read our process for reviewing NICE guidance